iiinova — where your digital self keeps evolving

Cizzle Bio and the CIZ1B Biomarker Blood Test for Lung Cancer were featured in GenomeWeb. The article examines the science behind CIZ1B and peer-reviewed results showing 94% sensitivity and 97% negative predictive value for stage I and II lung cancer. #CIZ1B #EarlyDetection

Cizzle Bio news graphic announcing its GenomeWeb feature about CIZ1B, a blood-based biomarker test for early-stage lung cancer detection.

000

Cizzle Bio, Inc. @cizzlebio.com · 20h

DFW clinicians: The CIZ1B test may provide an additional biomarker data point when assessing pulmonary nodules. It complements—not replaces—imaging and clinical judgment. Read the article: go.cizzlebio.com/vSfd7a

Cizzle Bio clinical-use graphic showing lungs and a blood sample with the question: A lung nodule is found—what information helps guide the next clinical decision?

Cizzle Bio graphic explaining that a finding is not a diagnosis and should be assessed using patient history, risk factors, imaging, and specialist evaluation.

Cizzle Bio graphic explaining that CIZ1B biomarker information may add clinical value within a comprehensive lung cancer assessment and does not replace imaging, biopsy, or clinical judgment.

001

Cizzle Bio, Inc. @cizzlebio.com · 25/09/2026

Today is World Lung Day. We’re joining the call for A Lifetime of Lung Health. At Cizzle Bio, we’re advancing CIZ1B, a biomarker blood test designed to support earlier lung cancer detection and complement standard-of-care approaches. Detect Early. Save Lives. #WorldLungDay #CizzleBio

World Lung Day graphic from Cizzle Bio featuring an illustrated pair of lungs and a woman outdoors with her eyes closed, taking a deep breath. Text reads, “Your lung health matters. Know your risk. Start the conversation.” Footer reads, “@cizzlebio” and “Detect Early. Save Lives.”

000

Cizzle Bio, Inc. @cizzlebio.com · 16/09/2026

Tonight, Cizzle Bio is joining the @preventcancer.org 2026 Annual Gala in Washington, D.C. We’re proud to support the Foundation’s cancer prevention and early detection work with a Bronze-Level pledge. Cizzle Biotechnology and CEO Allan Syms will also attend alongside Cizzle Bio and Bill Behnke.

Puerto Rico-themed event graphic announcing the Prevent Cancer Foundation’s 2026 Annual Gala tonight at the National Building Museum in Washington, D.C., with support from Cizzle Bio.

110

Cizzle Bio, Inc. @cizzlebio.com · 14/09/2026

On September 16, Cizzle Bio will join the @preventcancer.org 2026 Annual Gala in Washington, D.C. We’re proud to support the event with a Bronze-Level pledge, and our Founder and CEO, Bill Behnke, is serving on the Gala Committee and assisted in securing key sponsors. go.cizzlebio.com/fd3xDf

Puerto Rico-themed artwork for the Prevent Cancer Foundation’s 2026 Annual Gala, proudly supported by Cizzle Bio, on September 16 at the National Building Museum in Washington, D.C.

111

Cizzle Bio, Inc. @cizzlebio.com · 08/09/2026

Mark your calendar for: our Director of Communications Berkley Behnke and lymphoma survivor Ella Behnke are joining "Blood Cancer Uncovered: Answers, Treatment and Support", a TikTok Live series from GLOW and Blood Cancer United. Sept 16 at 7 PM ET, live in the TikTok app at @GLOWONCOLOGY.

000

Cizzle Bio, Inc. @cizzlebio.com · 04/09/2026

CIZ1B test is meant to support clinical assessment, not replace LDCT or clinical judgment. For licensed providers in DFW and San Antonio, ordering setup steps are available here: go.cizzlebio.com/SSj6gA

Graphic explaining that the CIZ1B blood test and LDCT imaging provide complementary information for lung cancer assessment — Cizzle Bio

010

Cizzle Bio, Inc. @cizzlebio.com · 01/09/2026

New peer-reviewed research in The Journal of Applied Laboratory Medicine supports the CIZ1B biomarker blood test — 94% sensitivity, 97% NPV in the early-stage cohort, evaluating the recently launched commercialized assay. Read the press release: go.cizzlebio.com/5aPGDU

Cizzle Bio graphic announcing new peer-reviewed research in The Journal of Applied Laboratory Medicine supporting the CIZ1B Biomarker Blood Test for early lung cancer detection. The study reported 94% sensitivity and a 97% negative predictive value in the early-stage cohort, strengthening the scientific foundation for CIZ1B. The graphic reads, “Evidence that moves early detection forward.”

000

Cizzle Bio, Inc. @cizzlebio.com · 28/08/2026

Provider FAQ: The CIZ1B Biomarker Blood Test can provide a biomarker-based tool to be used in conjunction with a comprehensive diagnostic assessment. Review clinician resources and ordering setup steps: go.cizzlebio.com/nDF5Ga

000

Cizzle Bio, Inc. @cizzlebio.com · 28/08/2026

Cizzle Bio attended Next Generation DX Summit 2026, where Dr. Lary Robinson of Moffitt Cancer Center presented on the potential of the CIZ1B biomarker in earlier lung cancer detection. Read our post-event recap and key takeaways from the presentation: buff.ly/D4O2T54 @moffitnews.bsky.social

cizzlebio.com

CIZ1B Biomarker Next Generation DX Summit 2026 Recap | Cizzle Bio, Inc.

Cizzle Bio recaps Dr. Lary Robinson’s Next Generation DX Summit 2026 presentation on CIZ1B, blood-based biomarkers, lung nodules, LDCT screening, and early lung cancer detection.

000

Cizzle Bio, Inc. @cizzlebio.com · 28/08/2026

CIZ1B Biomarker Blood Test clinician resources are available for licensed providers. Review clinical information and ordering setup steps: buff.ly/T4TeHfv

Cizzle Bio graphic promoting CIZ1B Biomarker Blood Test resources for licensed healthcare providers. Available resources include clinical performance, patient considerations, ordering setup, specimen collection, results access, patient education, and frequently asked questions. The design features a clinician displayed on a tablet alongside scientific imagery. Access clinician resources at https://www.cizzlebio.com/for-physicians/lung-cancer.

000

Cizzle Bio, Inc. @cizzlebio.com · 27/08/2026

From the Next Generation Dx Summit: Dr. Lary Robinson of Moffitt Cancer Center presented on the CIZ1B blood biomarker for early lung cancer detection — and how it could help assess indeterminate lung nodules and reduce unnecessary invasive procedures. Full announcement: buff.ly/tMMQDb7

prnewswire.com

Cizzle Bio Highlights CIZ1B Biomarker Blood Test for Lung Cancer at Next Generation Dx Summit

/PRNewswire/ -- Cizzle Bio Inc., a biotechnology company advancing biomarker blood tests for early cancer detection, today announced its participation in the...

000

Cizzle Bio, Inc. @cizzlebio.com · 21/08/2026

We're heading to the Next Gen DX Summit 2026 in DC, Aug 24–26. On Monday at 11:15 AM EDT, Dr. Lary Robinson of Moffitt Cancer Center presents on the current clinical study underway at Moffitt Cancer and the clinical potential of the CIZ1B biomarker in early lung cancer detection. buff.ly/ljgkWiL

Cizzle Bio will attend the 18th Annual Next Generation Dx Summit, August 24–26, 2026, at the Capital Hilton in Washington, D.C., and virtually. Dr. Lary Robinson of Moffitt Cancer Center will present “Potential of the CIZ1B Biomarker to Redefine Early Lung Cancer Detection” on August 24 at 11:15 a.m. EDT. The graphic features colorful wave patterns above the Washington Monument at dusk. Learn more at https://www.cizzlebio.com/events/next-generation-dx-summit-2026.

010

Cizzle Bio, Inc. @cizzlebio.com · 21/08/2026

Provider FAQ: How do licensed clinicians get set up to order CIZ1B? Providers in Dallas-Fort Worth and San Antonio, first step is account setup. Once setup is complete, physicians can access the provider portal to place orders and receive results. Review the ordering setup steps: buff.ly/W0VWQcT

Cizzle Bio provider-ordering guide graphic asking, “How can healthcare providers order the CIZ1B Lung Cancer Blood Test?” The image features a blood sample tube beneath a large question mark. Licensed providers can review setup steps and begin onboarding at https://www.cizzlebio.com/for-physicians/lung-cancer.

010

Cizzle Bio, Inc. @cizzlebio.com · 13/08/2026

San Antonio, the CIZ1B Biomarker Blood Test for Lung Cancer is now available through licensed healthcare providers. CIZ1B is designed to complement established diagnostic approaches, including LDCT, and support clinical decision-making. Patients: buff.ly/GuYec8X Clinicians: buff.ly/1zy9tqA

Cizzle Bio graphic announcing that the CIZ1B Biomarker Blood Test for earlier lung cancer detection is now available through licensed healthcare providers in San Antonio. The image features a South Texas map highlighting San Antonio, the Tower of the Americas, and a CIZ1B blood sample tube. Patient information: https://www.cizzlebio.com/for-patients/lung-cancer. Clinician resources: https://www.cizzlebio.com/for-physicians/lung-cancer.

110

Cizzle Bio, Inc. @cizzlebio.com · 11/08/2026

Dallas-Fort Worth: CIZ1B is now available through licensed healthcare providers. Patients can learn about CIZ1B and start a conversation with their healthcare provider: buff.ly/GuYec8X Clinicians can access ordering and clinical resources: buff.ly/1zy9tqA #CIZ1B #DallasHealthcare

000

Cizzle Bio, Inc. @cizzlebio.com · 07/08/2026

The CIZ1B Biomarker Blood Test for Lung Cancer is designed to complement LDCT and other clinical information, not replace them. Results should be interpreted by a healthcare provider as part of a comprehensive assessment. Learn more: buff.ly/m5AToVS #CizzleBio #CIZ1B #LungCancerFAQ #PatientEducation

Cizzle Bio carousel introducing frequently asked questions about the CIZ1B Biomarker Blood Test for earlier lung cancer detection. The graphic features a blood sample tube beneath a large question mark.

“Does CIZ1B replace LDCT?” No. The CIZ1B Biomarker Blood Test is designed to complement low-dose computed tomography and other standard-of-care approaches, not replace them.

“Does a CIZ1B result confirm or rule out cancer?” No. The test provides biomarker information that must be interpreted with other clinical information as part of a comprehensive assessment.

“How is the test performed?” A small blood sample is collected, securely packaged and transported, then processed and analyzed by a CLIA-certified laboratory partner.

100

Cizzle Bio, Inc. @cizzlebio.com · 06/08/2026

Primary care clinicians: CIZ1B adds biomarker data to lung cancer assessment alongside clinical judgment and appropriate imaging. Dallas and San Antonio providers can begin CIZ1B ordering setup: buff.ly/1zy9tqA #CIZ1B #PrimaryCare #LungCancer

Cizzle Bio clinician education graphic showing primary care’s role in earlier lung cancer detection. It presents three elements of clinical assessment: patient risk factors, appropriate imaging, and CIZ1B Biomarker Blood Test results as an additional data point supporting clinical decision-making. Dallas and San Antonio providers are invited to begin CIZ1B ordering setup.

020

Cizzle Bio, Inc. @cizzlebio.com · 03/08/2026

Cizzle Bio is collaborating with BioBridge Global (BBG) to expand access to the CIZ1B Biomarker Blood Test for Lung Cancer across South Texas. The minimally invasive blood test is designed to complement LDCT screening. Read more: buff.ly/mld2Beq #CIZ1B

Cizzle Bio and BBG Advanced Therapies announce a strategic laboratory collaboration to expand access to earlier lung cancer detection in South Texas. The graphic features a Texas map highlighting San Antonio and a blood sample tube.

Graphic announcing a new laboratory collaboration in South Texas. BBG Advanced Therapies, a BioBridge Global subsidiary, will be an additional CLIA-certified laboratory offering the CIZ1B Biomarker Blood Test for Lung Cancer.

U.S. map illustrating Cizzle Bio’s phased strategy to develop a national network of CLIA-certified laboratory partners. Texas is shown as the current foundation, with future partnerships intended to expand access across the country step by step.

Cizzle Bio and BBG Advanced Therapies graphic describing the collaboration as a meaningful step forward for South Texas and Cizzle Bio’s commitment to earlier lung cancer detection. Read the full press release at https://www.prnewswire.com/news-releases/cizzle-bio-expands-access-to-early-lung-cancer-detection-through-strategic-laboratory-collaboration-with-biobridge-global-in-south-texas-302840705.html.

010

Cizzle Bio, Inc. @cizzlebio.com · 31/07/2026

How does CIZ1B testing work? A licensed provider orders the test, a blood sample is collected and analyzed through a CLIA-certified laboratory, and the provider interprets the result alongside imaging, patient history, and other clinical findings. Patients: buff.ly/LnJBMtG

Cizzle Bio infographic titled “How CIZ1B Testing Works.” Four steps show a licensed healthcare provider ordering the test, collection of a blood sample of less than one tablespoon, analysis at a Dallas-based CLIA-certified laboratory, and clinical interpretation of the result alongside patient history, imaging, symptoms, risk factors, and other findings. Available through licensed healthcare providers in Dallas–Fort Worth and San Antonio. Learn more at https://www.cizzlebio.com/for-physicians/lung-cancer.

100

Cizzle Bio, Inc. @cizzlebio.com · 30/07/2026

The CIZ1B Biomarker Blood Test for Lung Cancer does not replace LDCT. It is designed to complement imaging and other clinical information by providing an additional biomarker-based tool to support patient assessment. Learn more: buff.ly/04BfMtE #CizzleBio #CIZ1B #LDCT #LungCancerScreening

Cizzle Bio graphic titled “CIZ1B + LDCT: Different tools. Complementary information.” An illustration pairs lungs representing LDCT imaging information with a CIZ1B blood sample tube representing biomarker information. The graphic states that CIZ1B supports—not replaces—established diagnostic approaches and that clinical decisions should consider the full clinical context. Learn more at https://www.cizzlebio.com/for-physicians/lung-cancer.

100

Cizzle Bio, Inc. @cizzlebio.com · 27/07/2026

Lung cancer risk is not the same for everyone. Smoking history matters, but family history, environmental exposure, chronic lung conditions, and other factors are also important. Start a conversation with your healthcare provider: buff.ly/P2rVLbv

Cizzle Bio graphic featuring a woman with an anatomical lung overlay and the message, “Lung cancer risk is not the same for everyone. Know your risk. Ask questions.” Risk factors shown include smoking history, family history, radon and environmental exposure, chronic lung conditions, and age and overall health. The graphic encourages starting a conversation with a healthcare provider.

000

Cizzle Bio, Inc. @cizzlebio.com · 24/07/2026

Healthcare providers in Dallas and San Antonio can now access clinical and ordering resources for the CIZ1B Biomarker Blood Test for Lung Cancer. Review performance information, patient considerations, specimen requirements, and ordering instructions: buff.ly/04BfMtE #CIZ1B #HealthcareProviders

Cizzle Bio graphic announcing that the CIZ1B test is available for clinician ordering in Dallas–Fort Worth and San Antonio. Resources cover clinical performance, patient considerations, ordering, specimen collection, results guidance, and patient education. A clinician holds a tablet beside a CIZ1B blood sample tube. Visit cizzlebio.com/for-physicians/lung-cancer.

010

Cizzle Bio, Inc. @cizzlebio.com · 22/07/2026

CIZ1B is now commercially available to licensed healthcare providers across Dallas-Fort Worth and San Antonio following laboratory validation at OmniHealth Diagnostics. Read the announcement: buff.ly/fKAKFGK #CIZ1B #EarlyDetection

Cizzle Bio commercial launch announcement for the CIZ1B biomarker blood test for lung cancer. The test is now available through licensed healthcare providers in Dallas–Fort Worth and San Antonio following laboratory validation at OmniHealth Diagnostics. Graphic features a CIZ1B blood sample tube and a map of Texas highlighting both metropolitan areas.

010

Cizzle Bio, Inc. @cizzlebio.com · 21/07/2026

Tomorrow marks an important step forward in Cizzle Bio’s mission to support earlier lung cancer detection. More information is coming. #CizzleBio #CIZ1B #DetectEarlySaveLives

000

Cizzle Bio, Inc. @cizzlebio.com · 09/07/2026

CIZ1B has completed laboratory validation at OmniHealth Diagnostics, marking an important step toward clinical availability. Cizzle Bio continues advancing CIZ1B as a minimally invasive biomarker blood test designed to support early lung cancer detection. #CizzleBio #CIZ1B

000

Cizzle Bio, Inc. @cizzlebio.com · 03/07/2026

Love Your Lungs Week is a reminder that lung health also means informed conversations, better tools, and earlier answers. Cizzle Bio is advancing CIZ1B, a minimally invasive biomarker blood test designed to support lung cancer detection as an adjunct to LDCT and standard clinical assessment.

100

Cizzle Bio, Inc. @cizzlebio.com · 29/06/2026

Love Your Lungs Week is a reminder to protect lung health, know your risk factors, and ask questions about early detection. At Cizzle Bio, we are advancing CIZ1B, a biomarker blood test for lung cancer coming soon to licensed U.S. healthcare providers. Protect your lungs. Know your risk.

100

Cizzle Bio, Inc. @cizzlebio.com · 27/06/2026

Fact 20: Detecting cancer early is central to Cizzle Bio’s mission: Detect Early. Save Lives. As GO2 for Lung Cancer’s June 7-27 campaign closes, Cizzle Bio remains committed to awareness, education, and progress in lung cancer detection. #StepUpFor20 #LungCancerAwareness #EarlyDetection #CizzleBio

000

Cizzle Bio, Inc. @cizzlebio.com · 26/06/2026

Fact 19: Early detection is central to improving outcomes and supporting more timely clinical decisions—helping clinicians and patients move forward with greater clarity. #StepUpFor20 #LungCancerAwareness #EarlyDetection #CizzleBio

000

Cizzle Bio, Inc. @cizzlebio.com · 26/06/2026

Fact 18: Cizzle Bio is advancing CIZ1B, a biomarker blood test for lung cancer, coming soon to licensed U.S. healthcare providers. CIZ1B is designed to support early lung cancer detection through a minimally invasive blood draw and serve as an adjunct tool in clinical assessment. #StepUpFor20

100

Cizzle Bio, Inc. @cizzlebio.com · 25/06/2026

Fact 17: Biomarker science is helping change how clinicians understand and detect cancer. Cizzle Bio is focused on advancing biomarker blood tests that support earlier detection and provide clinicians with meaningful information in patient care. #StepUpFor20 #LungCancerAwareness #EarlyDetection

110

Cizzle Bio, Inc. @cizzlebio.com · 24/06/2026

Cizzle Bio will attend the AVBCC SoCal Regional Collaborative on June 26 at City of Hope. Looking forward to connecting with leaders across oncology and value-based cancer care. buff.ly/QMPuIza #Oncology #ValueBasedCare #CancerCare

buff.ly

010

Cizzle Bio, Inc. @cizzlebio.com · 23/06/2026

Fact 16: Awareness campaigns can help people understand risk factors and start important conversations with their healthcare providers. Education can be a first step toward action. When you understand your risk, you can be better equipped to ask questions and seek guidance. #StepUpFor20

100

Cizzle Bio, Inc. @cizzlebio.com · 22/06/2026

Fact 15: Lung cancer affects people across many backgrounds, including people who have never smoked. Awareness must include everyone. Lung cancer education should be clear, compassionate, and free from stigma. #StepUpFor20 #LungCancerAwareness #EarlyDetection #CizzleBio

000

Cizzle Bio, Inc. @cizzlebio.com · 21/06/2026

Fact 14: Lung cancer stigma can prevent people from seeking support. Everyone impacted by lung cancer deserves compassion and care—because anyone with lungs can get lung cancer.

100

Cizzle Bio, Inc. @cizzlebio.com · 20/06/2026

Fact 13: Persistent cough, shortness of breath, chest pain, coughing up blood, and unexplained weight loss are symptoms that you should discuss with your healthcare provider. Listening to your body matters. Persistent symptoms should never be ignored. #StepUpFor20 #LungCancerAwareness

110

Cizzle Bio, Inc. @cizzlebio.com · 19/06/2026

Fact 12: Earlier detection can create more opportunities for timely treatment and better outcomes. This is at the heart of Cizzle Bio’s mission: helping detect cancer early, when treatment is most effective. #StepUpFor20 #LungCancerAwareness #EarlyDetection #CizzleBio

000

Cizzle Bio, Inc. @cizzlebio.com · 19/06/2026

Fact 11: Lung cancer may not cause noticeable symptoms in its early stages. Because symptoms can appear later, understanding risk factors and having informed conversations with a healthcare provider are important steps in supporting earlier detection. #StepUpFor20 #LungCancerAwareness

100

Cizzle Bio, Inc. @cizzlebio.com · 18/06/2026

Fact 10: Low-dose CT (LDCT) is the established screening tool for people who meet lung cancer screening criteria. Cizzle Bio is advancing CIZ1B as a biomarker blood test designed to support earlier lung cancer detection as an adjunct tool in clinical assessment.

110

Cizzle Bio, Inc. @cizzlebio.com · 16/06/2026

Fact 9: The U.S. Preventive Services Task Force recommends annual lung cancer screening for adults ages 50 to 80 with a 20 pack-year smoking history who currently smoke or quit within the past 15 years.

100

Cizzle Bio, Inc. @cizzlebio.com · 16/06/2026

CIZ1B has completed laboratory validation at OmniHealth Diagnostics, marking an important step toward near-term clinical availability. Cizzle Bio continues to advance biomarker science to support earlier lung cancer detection and better-informed care.

100

Cizzle Bio, Inc. @cizzlebio.com · 15/06/2026

Fact 8: Chronic lung conditions such as COPD or emphysema may increase lung cancer risk. For individuals with chronic lung conditions, ongoing conversations about lung health and cancer risk are especially important. #StepUpFor20 #LungCancerAwareness #EarlyDetection #CizzleBio

000

Cizzle Bio, Inc. @cizzlebio.com · 14/06/2026

Fact 7: Family history can play a role in lung cancer risk. Knowing your family history can help guide conversations with a healthcare provider. Family health history can be an important part of proactive care because it can help patients and clinicians better understand risk and next steps.

110

Cizzle Bio, Inc. @cizzlebio.com · 13/06/2026

Fact 6: Radon exposure is an important lung cancer risk factor, especially because it can be present in your house even though you can’t see or smell it. Some risks are invisible. Awareness can help people take practical steps to better understand and protect their lung health.

100

Cizzle Bio, Inc. @cizzlebio.com · 12/06/2026

Fact 5: Smoking is not the only risk factor for lung cancer. People with no smoking history can also be diagnosed. Lung cancer can affect many different people. Reducing stigma helps create space for earlier conversations, better support, and more compassionate care.

100

Cizzle Bio, Inc. @cizzlebio.com · 12/06/2026

Fact 4: Lung cancer risk can be shaped by smoking history, family history, and chronic lung conditions—as well as exposure to secondhand smoke, radon, asbestos, and air pollution. Risk is not always simple or tied to one factor.

100

Cizzle Bio, Inc. @cizzlebio.com · 11/06/2026

Fact 3: Most lung cancers are non-small cell lung cancer, also known as NSCLC. Because NSCLC represents the majority of lung cancer cases, tools that support early detection may play an important role in improving how lung cancer is identified and managed.

100

Cizzle Bio, Inc. @cizzlebio.com · 09/06/2026

Fact 2: There are two main types of lung cancer: non-small cell lung cancer and small cell lung cancer. Understanding lung cancer begins with education. The more patients and families know, the better prepared they are to have informed conversations with healthcare providers.

100

Cizzle Bio, Inc. @cizzlebio.com · 08/06/2026

Fact 1: Lung cancer remains one of the leading causes of cancer death in the United States and globally. Awareness and early detection matter. At Cizzle Bio, we believe early detection is one of the most important ways to help change the future of lung cancer care.

100